Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXFree Report) in a research report released on Thursday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE:BTX opened at $1.66 on Thursday. The business’s fifty day moving average price is $1.72 and its two-hundred day moving average price is $1.89. The stock has a market cap of $97.40 million, a PE ratio of -0.73 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC increased its position in Brooklyn ImmunoTherapeutics Inc (NYSE:BTXFree Report) by 20.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,459,626 shares of the company’s stock after buying an additional 243,826 shares during the period. Renaissance Technologies LLC owned about 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 as of its most recent SEC filing. Institutional investors own 26.00% of the company’s stock.

Brooklyn ImmunoTherapeutics Company Profile

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Featured Stories

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.